HOLD residual BMY exposure — 9/21 reflection prohibits entry into broken momentum despite compelling structural valuation; preserve carry and floor optionality until technical repair or binary catalysts (Q3 2026 earnings, CYTK ruling) resolve the setup.
HOLD is the calibrated rating that respects both the 9/21 binding reflection (do not add into broken momentum) and the 9/17 binding reflection (do not trim further into intact floor). The aggressive analyst's structural valuation case is compelling but his failure to update his framework after the 9/21 outcome — re-deploying the same "RSI at 37 in an uptrend is a sale price" rhetoric that was wrong 24 hours ago — means his entry-timing judgment cannot be credited. The conservative analyst's demand for technical confirmation before adding is validated by the most recent empirical outcome. The neutral analyst's execution refinements (smaller Layer 1, tighter stop) are operationally sensible but do not address the binding entry-timing prohibition. The dividend is paid to wait for one of the defined re-engagement triggers, not paid to chase entry into broken momentum.
| Position | Action |
|---|---|
| Default (income-focused mandates) | Collect 4% dividend yield on residual position while waiting for technical repair or price weakness toward $58-60; covered yield materially reduces cost of being patient on constructive view |
| Default (total-return mandates) | Preserve capital in cash/short-duration Treasuries at 5%+ risk-free yield rather than deploy into broken momentum empirically validated as alpha-leaking |
| Do NOT exceed prior calibrated weight | Maintain current residual position sizing ceiling; do not scale up into broken momentum |
| Do NOT rotate into PFE or other pharma | Correlated sector risk per all three current analysts — hedge via non-pharma exposure only |
BMY is deeply undervalued at 9.48x forward P/E (35–40% discount to peers), delivering best-in-class margins and triple-digit EPS growth while its diversified pipeline backfills the Eliquis patent cliff, with the 4%+ dividend providing a defensive floor in a hawkish Fed regime.
| Indicator | Value | Signal |
|---|---|---|
| close | 62.25 | neutral |
| 10_ema | 63.54 | bearish |
| 50_sma | 64.17 | bearish |
| 200_sma | 58.24 | bullish |
| rsi | 37.10 | bearish |
| macd | -0.56 | bearish |
| macd_signal | -0.05 | bearish |
| macd_histogram | -0.50 | bearish |
| bollinger_mid | 65.20 | neutral |
| bollinger_upper | 69.24 | neutral |
| bollinger_lower | 61.16 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed test and hold of 200 SMA ($58.24) with bullish daily divergence
Then: Add 25% of intended Overweight size
↩ rebuts: “Bear framing of 'Eliquis patent cliff destroying revenue in 2027' ignores credible backfill story”
EV: +18–25% total return potential; target $70–$75 over 12 months · concedes: One pipeline program (Orum) was discontinued and senior R&D leader (Plenge) left to BioMarin - bear calls this pipeline weakness, bull frames as portfolio rationalization post-acquisition integration; Eliquis patent expiration in 2027 is real and will erode revenue - bear concern is valid, bull argues backfill story is credible and already discounted into 9.48x multiple; Short-term momentum is broken - death cross between 10 EMA and 50 SMA is real, bear technical analysis is technically correct on short-term indicators
BMY at $62.25 is not a bargain but a value trap — the 9.48x forward P/E appropriately discounts a $10B+ Eliquis revenue cliff in 2027, uncertain pipeline backfill, severe technical breakdown with institutional distribution, and a leveraged balance sheet that threatens dividend sustainability.
EV: -10% to -15% · concedes: Cobenfy is a first-mover in a new mechanism (M1/M4 muscarinic agonist); First-mover advantage in new mechanism does have some value; Total pipeline peak could reach $9-13 billion if all assets hit bull-case; 4% dividend is currently covered at 1.57x; Debt paydown of $6B YTD shows some deleveraging progress; RSI at 37.10 is approaching oversold territory (though room to fall to 30); If all pipeline assets execute perfectly, the backfill could approach the Eliquis hole
→ vs conservative: Waiting for technical confirmation (RSI, MACD, pullback to 200 SMA at 58.24) is paralysis dressed as discipline — suggesting to wait for 7% more decline before buying is not risk management
→ vs conservative: Patent cliff is the most overcooked fear — already embedded in 9.48x multiple; BMY is actively backfilling with real revenue-generating assets (Cobenfy, Opdivo SubQ, Sotyktu, Augtyro, Krazati) not speculative M&A optionality
→ vs conservative: Hawkish Fed thesis inverts — higher-for-longer rates favor defensive 0.227 beta yield anchor over growth names facing multiple compression
→ vs conservative: Applying high-growth high-momentum playbook to a defensive value name is wrong framework — BMY is a yield-anchored compounder, not a timing trade
→ vs neutral: "Balanced risk-reward" is incorrect framing — at 9.48x forward P/E with 34.4% operating margins and 46.6% ROE, the description should be "mispriced," not "balanced"
→ vs neutral: Waiting for pullback to 59 before recommending action misses that layered entry structure already incorporates pullback optionality — hesitation means watching the setup resolve without participation
→ vs conservative: "Wait until pipeline works" essentially means "wait until multiple expansion already happened" — early position captures rerating, cautious stance misses it
| atr | 1.34 | neutral |
| vwma | 63.93 | bearish |
Support: 61.16 · 58.24 · 57.03 | Resistance: 63.54 · 64.17 · 65.2 · 67.66 · 68.09
BMY exhibits a clear short-term bearish technical setup with price ($62.25) trading below all key short- and medium-term moving averages, RSI near-oversold at 37.10, and MACD histogram expanding negatively at −0.50, confirming accelerating downside momentum. The September 18 mega-volume session (36.85M shares vs. 7–14M typical) on a weak close signals institutional distribution rather than routine profit-taking. However, the long-term trend remains intact as price sits ~7% above the 200 SMA at $58.24; the critical support level is the 200 SMA, with a break below $58.24 required to flip the broader year-long uptrend to neutral/bearish.
Market Cap
$127.16 billion
P/E Ratio (TTM)
13.71
Forward P/E
9.48
PEG Ratio
17.44
Price / Book
5.70
EPS (TTM)
$4.54
Forward EPS
$6.56
Dividend Yield
4.02%
Beta
0.227
52-Week High
$68.64
52-Week Low
$42.52
50-Day MA
$64.11
200-Day MA
$58.93
Revenue (TTM)
$49.19 B
Gross Profit
$35.25 B
Gross Margin
71.6%
EBITDA
$18.93 B
Net Income
$9.28 B
Operating Margin
34.4%
Profit Margin
18.9%
Return on Equity
46.6%
Return on Assets
10.7%
Total Assets
$87.63 B
Stockholders' Equity
$22.32 B
Total Debt
$45.05 B
Net Debt
$34.40 B
Cash + ST Investments
$11.07 B
Working Capital
$9.92 B
Current Ratio
1.53
Debt / Equity
201.9%
Tangible Book Value
–$17.05 B
Goodwill
$21.74 B
Other Intangibles
$17.63 B
TTM Free Cash Flow
$8.11 B
Annual Dividend
$5.15 B
FCF / Dividend Coverage
1.6x
Diluted Share Count
~2.048B
Quarterly Dividend
$0.63
Annual Dividend Per Share
$2.52
Q2 2026 Revenue
$12.97B
Q2 2026 Diluted EPS
$1.62
Q2 2026 Operating Cash Flow
$3.39 B
Q2 2026 Free Cash Flow
$3.09 B
Q2 2026 CapEx
($0.31 B)
Q2 2026 Dividend Paid
($1.29 B)
Q2 2026 Debt Repayment
($1.22 B)
Revenue Q2 26 vs Q2 25 Growth
+5.7%
EPS Q2 26 vs Q2 25 Growth
+153%
Forward EPS vs TTM Growth
+44.6%
Distance from 52-Week High
~9% below
Strengths
Concerns
BMY presents a balanced risk/reward profile with a HOLD rating, trading at a forward P/E of 9.48x with a 4.02% dividend yield that is well-covered by FCF. The company demonstrated strong operational improvement with EPS of $1.62 in Q2 2026 (up 153% YoY) and revenue reacceleration to 5.7% growth, while actively deleveraging with $6B in debt repaid over 9 months. The principal overhang is the Eliquis patent cliff (2026–27) expected to pressure revenue by $5–10B, making pipeline execution (Cobenfy, Opdivo subq, radioligands) critical for backfilling lost revenue.
Macro: The dominant macro driver is a hawkish Fed surprise: the Fed raised rates for the first time since 2023, with markets pricing a 96% probability of no cuts in 2026 (up 2.8pp WoW). This higher-for-longer rate regime creates multiple compression risk for growth-by-pipeline stories like BMY, while making the ~4% dividend yield more attractive relative to bonds. USD strength from rate hikes creates FX headwinds for BMY's non-US revenue translation. On the positive side, recession odds have fallen to 8% (down 13pp WoW), supporting risk assets and defensive healthcare names broadly.